In a groundbreaking study published in the February 2026 issue of Oncoscience, researchers led by Sunny Kahlon from the University of South Florida’s Department of Molecular Medicine have unveiled compelling evidence linking MYC gene amplification with diminished immunogenicity in metastatic prostate cancer. This comprehensive investigation deploys sophisticated genomic analyses to unravel the intricate relationship between MYC copy-number changes and the adaptive immune landscape within prostate tumors, offering novel insights into the prognostic implications and potential therapeutic avenues for this aggressive form of cancer.
MYC, a well-known oncogene implicated in numerous cancers, frequently undergoes copy-number amplification, driving tumor progression and metastasis. The team utilized extensive genomics datasets including The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD), WCDT-MCRPC, and CMI-MPC cohorts to meticulously quantify MYC copy numbers across a spectrum of prostate cancer samples. Their analyses confirmed a higher prevalence of MYC amplification in metastatic tumors compared to primary ones, underscoring MYC’s role in advancing malignancy and impacting disease trajectory.
To assess tumor immunogenicity, the researchers innovatively applied computational approaches to recover adaptive immune receptor (IR) recombination reads—specifically immunoglobulin heavy (IGH), kappa (IGK), lambda (IGL) chains for B cells and T cell receptor alpha (TRA), beta (TRB), gamma (TRG), delta (TRD) chains for T cells—from RNA sequencing and whole-genome sequencing data of tumor samples. This innovative method allowed them to infer the richness and diversity of adaptive immune cell infiltration without relying on traditional immunohistochemistry, providing a high-resolution snapshot of the tumor immune microenvironment.
Strikingly, metastatic prostate tumors with MYC amplification exhibited a significantly lower recovery of adaptive IR recombination reads, suggesting a markedly reduced presence or diversity of tumor-infiltrating lymphocytes, particularly B cells. This decline in adaptive immune signatures was corroborated by the reduced expression of multiple immune marker genes known to be pivotal in mediating anti-tumor immunity, including CD19, CD22, CD33, CD68, and MS4A1, among others. The suppressed immunogenic milieu in MYC-amplified tumors points to a potential mechanism by which these cancers evade immune surveillance, fostering their progression.
Clinically, the impact of MYC amplification extended beyond immune evasion; the study demonstrated a clear association between MYC copy-number gains and poorer progression-free survival (PFS) outcomes in patients with metastatic prostate cancer. This correlation emphasizes MYC amplification as a robust biomarker for aggressive disease and highlights its potential utility in stratifying patients based on risk, guiding clinical management and therapeutic decision-making.
Importantly, the diminution in immune receptor read recovery and immune marker expression was most pronounced for B-cell–related sequences, revealing a possible preferential impairment of B-cell mediated immunity in MYC-driven metastatic tumors. This finding is particularly intriguing, given the emerging recognition of B cells in orchestrating anti-tumor responses and their modulatory roles within the tumor microenvironment.
The investigators caution that their conclusions primarily arise from computational mining of existing genomic datasets. They underscore the need for follow-up experimental validation, including PCR-based assays for immune receptor repertoires and prospective patient sampling to authenticate and expand upon these observations. Despite these caveats, the data robustly suggest that MYC amplification contributes to an immunologically “cold” tumor phenotype, resistant to immune checkpoint blockade therapies.
This revelation holds transformative implications for immunotherapy in metastatic prostate cancer. Given the suppressed adaptive immune footprint in MYC-amplified tumors, patients harboring such alterations might be less responsive to current immunotherapeutic regimens. Therefore, targeted strategies aiming to restore or enhance T-cell and B-cell infiltration and function could be pivotal in overcoming resistance and improving clinical outcomes.
Consequently, the study opens new research avenues focused on understanding the molecular underpinnings of MYC-driven immunosuppression in prostate cancer. It also supports the rationale for integrating MYC genomic status into precision oncology frameworks to tailor immunotherapeutic interventions, potentially combining MYC inhibition with modulators of the immune microenvironment.
In summary, this pioneering investigation bridges oncogenic MYC amplification with impaired tumor immunogenicity and adverse clinical prognosis in metastatic prostate cancer. It champions the use of adaptive immune receptor repertoires mined from existing RNAseq and genome sequencing data as a novel biomarker reflecting tumor-immune dynamics. By illuminating these complex interactions, this research lays the foundation for future therapeutic innovations aimed at reactivating anti-tumor immunity in this challenging disease context.
The study exemplifies the power of computational genomics for unlocking hidden insights within vast sequencing datasets to decipher tumor biology and immune interactions. As prostate cancer remains a leading cause of cancer mortality among men worldwide, these insights are urgently needed to refine diagnostic tools and enhance therapeutic efficacy through immunomodulation, improving survival outcomes across this vulnerable patient population.
Subject of Research:
Not applicable
Article Title:
Reduced immunogenicity of MYC amplified, metastatic prostate cancer
News Publication Date:
7-Feb-2026
Web References:
https://doi.org/10.18632/oncoscience.644
Image Credits:
Copyright © 2026 Kahlon et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).
Keywords:
cancer, prostate cancer, MYC amplification, adaptive immune receptor recombinations, reduced immunogenicity, RNAseq files
Tags: adaptive immune receptor recombination in cancerB cell receptor diversity in cancerCMI-MPC prostate cancer researchdecreased tumor immunogenicity in prostate cancergenomic analysis of MYC copy numberimmune landscape of prostate tumorsMYC gene amplification in metastatic prostate cancerprognostic biomarkers in metastatic prostate cancerT cell receptor profiling in tumorsTCGA-PRAD prostate cancer genomicstherapeutic targets for MYC-amplified prostate cancerWCDT-MCRPC cohort study
